AstraZeneca's Vaccine Data Is Still Good Enough for U.S. Authorization

Brian Orelli, PhD and Keith Speights, The Motley Fool
·4 min read

AstraZeneca (NASDAQ: AZN) created some drama releasing interim COVID-19 vaccine results just days before the pharma was able to generate final results from the U.S.-based phase 3 study. In this video from Motley Fool Live, recorded on March 29, contributors Brian Orelli and Keith Speights discuss the brouhaha, and what it means for AstraZeneca's long-term prospects. Brian Orelli: AstraZeneca reported a final data from its COVID-19 vaccine -- that it went from 79% efficacy at preventing symptomatic COVID-19 for the interim look and then at the final look it was 76%.